PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
ARCA biopharma, Inc. (ABIO)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS00211Y5069
CUSIP00211Y506
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$47.58M
EPS (TTM)-$0.42
Total Revenue (TTM)$176.00K
Gross Profit (TTM)$75.00K
EBITDA (TTM)-$7.94M
Year Range$1.56 - $4.49
Target Price$7.00
Short %39.50%
Short Ratio24.99

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


ARCA biopharma, Inc.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in ARCA biopharma, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%20.00%2024FebruaryMarchAprilMayJune
-100.00%
15.17%
ABIO (ARCA biopharma, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

ARCA biopharma, Inc. had a return of 96.47% year-to-date (YTD) and 59.05% in the last 12 months. Over the past 10 years, ARCA biopharma, Inc. had an annualized return of -33.07%, while the S&P 500 had an annualized return of 10.86%, indicating that ARCA biopharma, Inc. did not perform as well as the benchmark.


PeriodReturnBenchmark
Year-To-Date96.47%13.65%
1 month-1.76%3.82%
6 months87.64%15.17%
1 year59.05%24.08%
5 years (annualized)-12.47%13.46%
10 years (annualized)-33.07%10.86%

Monthly Returns

The table below presents the monthly returns of ABIO, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-6.47%3.77%6.67%98.30%6.02%96.47%
2023-7.17%0.00%-9.55%0.50%5.50%-3.79%0.49%0.49%-1.95%-10.95%1.68%-6.59%-28.27%
2022-12.09%7.41%13.30%3.04%0.84%4.18%-1.61%-4.49%-11.97%4.37%-2.79%13.40%10.23%
20214.74%0.24%-13.30%-5.75%1.45%0.00%-9.46%-2.22%-4.21%-7.43%-13.69%-9.09%-46.38%
2020-8.21%-28.65%-25.40%31.18%244.26%-47.46%5.74%-21.71%-19.34%-12.90%10.13%-5.42%-29.78%
201925.91%12.81%-21.13%-23.27%12.21%26.42%-6.42%-17.96%-4.81%-7.47%13.13%1.98%-4.87%
201822.22%-50.91%-38.35%5.11%5.92%-0.00%49.28%-25.78%-9.09%21.43%-24.16%-35.33%-75.30%
2017-7.02%-3.77%-0.00%3.92%-9.43%0.00%-22.92%-40.54%4.55%5.39%7.26%3.85%-52.63%
2016-18.49%-9.23%0.87%21.33%-20.31%-13.56%6.21%-7.79%-0.35%-22.26%6.82%21.28%-38.71%
2015-25.55%-1.41%12.87%1.25%-1.25%45.57%-6.96%-15.89%-21.27%3.23%12.89%-19.55%-30.34%
201416.07%-3.59%-1.06%-13.44%-8.70%-0.68%-2.06%-2.09%-11.43%-9.68%-26.92%16.51%-43.24%
2013127.11%-38.59%-25.16%0.00%-31.93%-20.37%8.53%-6.43%22.14%-15.00%2.21%20.86%-26.32%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current risk-adjusted rank of ABIO is 81, placing it in the top 19% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.


The Risk-Adjusted Performance Rank of ABIO is 8181
ABIO (ARCA biopharma, Inc.)
The Sharpe Ratio Rank of ABIO is 6868Sharpe Ratio Rank
The Sortino Ratio Rank of ABIO is 9191Sortino Ratio Rank
The Omega Ratio Rank of ABIO is 9393Omega Ratio Rank
The Calmar Ratio Rank of ABIO is 7373Calmar Ratio Rank
The Martin Ratio Rank of ABIO is 8080Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for ARCA biopharma, Inc. (ABIO) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


ABIO
Sharpe ratio
The chart of Sharpe ratio for ABIO, currently valued at 0.60, compared to the broader market-2.00-1.000.001.002.003.000.60
Sortino ratio
The chart of Sortino ratio for ABIO, currently valued at 2.92, compared to the broader market-4.00-2.000.002.004.006.002.92
Omega ratio
The chart of Omega ratio for ABIO, currently valued at 1.44, compared to the broader market0.501.001.502.001.44
Calmar ratio
The chart of Calmar ratio for ABIO, currently valued at 0.58, compared to the broader market0.002.004.006.000.58
Martin ratio
The chart of Martin ratio for ABIO, currently valued at 4.39, compared to the broader market0.0010.0020.0030.004.39
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 2.20, compared to the broader market-2.00-1.000.001.002.003.002.20
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 3.12, compared to the broader market-4.00-2.000.002.004.006.003.12
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.39, compared to the broader market0.501.001.502.001.39
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.76, compared to the broader market0.002.004.006.001.76
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 8.26, compared to the broader market0.0010.0020.0030.008.26

Sharpe Ratio

The current ARCA biopharma, Inc. Sharpe ratio is 0.60. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of ARCA biopharma, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-2.00-1.000.001.002.003.002024FebruaryMarchAprilMayJune
0.60
2.20
ABIO (ARCA biopharma, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


ARCA biopharma, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%2024FebruaryMarchAprilMayJune
-100.00%
0
ABIO (ARCA biopharma, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the ARCA biopharma, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the ARCA biopharma, Inc. was 100.00%, occurring on Feb 1, 2024. The portfolio has not yet recovered.

The current ARCA biopharma, Inc. drawdown is 100.00%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-100%Nov 16, 20005837Feb 1, 2024
-87.35%Sep 29, 1997385Apr 9, 1999190Jan 7, 2000575
-14.06%Aug 12, 19976Aug 19, 199714Sep 9, 199720
-7.58%May 26, 20001May 26, 20001May 30, 20002
-4.74%Apr 17, 20001Apr 17, 20001Apr 18, 20002

Volatility

Volatility Chart

The current ARCA biopharma, Inc. volatility is 27.27%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%60.00%70.00%2024FebruaryMarchAprilMayJune
27.27%
2.51%
ABIO (ARCA biopharma, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of ARCA biopharma, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items